CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 172 enrolled
Drug / intervention
IBI-10090drug
Likely dose
Not stated in record
Key inclusion· 1
  • ✓Scheduled for unilateral cataract surgery
Key exclusion· 1
  • ✕Ocular, topical, or oral corticosteroids within 7 days prior to surgery

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01606735
NCT01606735Phase 2Completed
CompareCT.gov

A Multicenter, Randomized, Double-masked, Dose-ranging, Phase 2 Study to Evaluate the Efficacy and Safety of IBI-10090 for the Treatment of Inflammation Associated With Ocular Surgery

ICON Bioscience Inc·interventional·Posted May 28, 2012·Updated Sep 22, 2014

In Brief

A Phase 2 clinical trial evaluating IBI-10090 for Inflammation Associated With Cataract Surgery. Completed, enrolled 172 participants across 2 sites.

Detailed Summary

This study will test the efficacy and safety of IBI-10090 in the treatment of ocular inflammation after ocular surgery.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsInflammation Associated With Cataract Surgery
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedMay 28, 2012
Enrollment StartApr 1, 2012
Primary CompletionMar 1, 2013
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 14.1 years ago

Interventions

IBI-10090drug

dexamethasone